|
US6710174B2
(en)
|
2001-09-13 |
2004-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of vascular endothelial growth factor receptor-1 expression
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
US7396664B2
(en)
|
1999-06-08 |
2008-07-08 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
US7087411B2
(en)
*
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US6833349B2
(en)
*
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
AU2002248372B8
(en)
|
2001-01-19 |
2008-03-20 |
Vegenics Limited |
FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy
|
|
US6734017B2
(en)
|
2001-09-28 |
2004-05-11 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of vascular endothelial growth factor receptor-2 expression
|
|
ATE500842T1
(de)
|
2002-05-04 |
2011-03-15 |
Acorda Therapeutics Inc |
Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
|
|
ATE354592T1
(de)
*
|
2003-03-28 |
2007-03-15 |
Regeneron Pharma |
Vegf-antagonisten zur behandlung von diabetes
|
|
AU2004247025B8
(en)
*
|
2003-05-16 |
2011-06-30 |
Acorda Therapeutics, Inc. |
Fusion proteins for the treatment of CNS
|
|
US7959914B2
(en)
|
2003-05-16 |
2011-06-14 |
Acorda Therapeutics, Inc. |
Methods of reducing extravasation of inflammatory cells
|
|
US7429375B2
(en)
|
2003-05-16 |
2008-09-30 |
Acorda Therapeutics, Inc. |
Proteoglycan degrading mutants for the treatment of CNS
|
|
WO2004106378A2
(en)
*
|
2003-05-28 |
2004-12-09 |
Regeneron Pharmaceuticals, Inc. |
Method of treating corneal transplant rejection by using vegf antagonists
|
|
US7186699B2
(en)
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
|
WO2004110490A2
(en)
*
|
2003-06-06 |
2004-12-23 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitors for tumor regression
|
|
US7399612B2
(en)
|
2003-06-30 |
2008-07-15 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
AR046510A1
(es)
*
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
WO2005016369A1
(en)
*
|
2003-08-06 |
2005-02-24 |
Regeneron Pharmaceuticals, Inc. |
Use of a vegf antagonist in combination with radiation therapy
|
|
AU2005244933B2
(en)
|
2004-05-18 |
2011-08-04 |
Acorda Therapeutics, Inc. |
Methods of purifying chondroitinase and stable formulations thereof
|
|
JP4680997B2
(ja)
*
|
2004-06-08 |
2011-05-11 |
ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド |
血管新生を阻害するキメラタンパク質およびその利用
|
|
WO2005123104A2
(en)
|
2004-06-10 |
2005-12-29 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitors for the treatment of human cancer
|
|
EP1755645A2
(en)
*
|
2004-06-18 |
2007-02-28 |
Regeneron Pharmaceuticals, Inc. |
Vegf inhibitors for the treatment of malignant pleural effusion
|
|
CA2567795C
(en)
|
2004-07-30 |
2013-06-11 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating type i diabetes by blocking vegf-mediated activity
|
|
EP2229956B1
(en)
|
2004-09-13 |
2013-04-24 |
Genzyme Corporation |
Multimeric constructs
|
|
FR2878749B1
(fr)
*
|
2004-12-03 |
2007-12-21 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
|
|
CA2621047A1
(en)
|
2005-02-02 |
2006-08-24 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a vegf inhibitor
|
|
SI1861116T1
(sl)
|
2005-03-25 |
2015-12-31 |
Regeneron Pharmaceuticals, Inc. |
Formulacije antagonistov VEGF
|
|
AU2006294755B2
(en)
|
2005-09-26 |
2012-04-19 |
Acorda Therapeutics, Inc. |
Compositions and methods of using chondroitinase ABCI mutants
|
|
NZ568739A
(en)
†
|
2005-12-16 |
2010-09-30 |
Regeneron Pharma |
Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists
|
|
FR2895258B1
(fr)
|
2005-12-22 |
2008-03-21 |
Aventis Pharma Sa |
Combinaison comprenant de la combretastatine et des agents anticancereux
|
|
US8216575B2
(en)
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
|
CN100502945C
(zh)
*
|
2006-03-31 |
2009-06-24 |
成都康弘生物科技有限公司 |
Vegf受体融合蛋白在治疗眼睛疾病中的应用
|
|
SI2364691T1
(sl)
|
2006-06-16 |
2013-08-30 |
Regeneron Pharmaceuticals, Inc. |
Formulacije antagonista VEGF, primerne za intravitrealno dajanje
|
|
PL2066694T3
(pl)
|
2006-09-29 |
2016-04-29 |
Oncomed Pharm Inc |
Kompozycje i sposoby diagnozowania i leczenia nowotworu
|
|
CA3086902C
(en)
|
2006-10-10 |
2021-11-09 |
Acorda Therapeutics, Inc. |
Compositions and methods of using chondroitinase abci mutants
|
|
FR2918279B1
(fr)
*
|
2007-07-05 |
2010-10-22 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
|
|
CN101575379B
(zh)
*
|
2008-05-09 |
2012-05-30 |
上海抗体药物国家工程研究中心有限公司 |
可溶性vegfr双功能融合受体、其制备方法及用途
|
|
US8901076B2
(en)
|
2008-11-03 |
2014-12-02 |
Molecular Partner AG |
Binding proteins inhibiting the VEGF-A receptor interaction
|
|
CN101838329A
(zh)
*
|
2009-03-18 |
2010-09-22 |
嘉和生物药业有限公司 |
抗血管新生融合蛋白
|
|
EP2488204B1
(en)
|
2009-10-16 |
2016-04-06 |
Oncomed Pharmaceuticals, Inc. |
Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
|
|
TWI510246B
(zh)
*
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
|
|
DK2601214T3
(en)
|
2010-08-06 |
2018-02-05 |
Genzyme Corp |
VEGF ANTAGONIST COMPOSITIONS AND APPLICATIONS THEREOF
|
|
EP2662385A4
(en)
*
|
2011-01-07 |
2015-11-11 |
Chugai Pharmaceutical Co Ltd |
METHOD FOR IMPROVING THE PHYSICAL PROPERTIES OF ANTIBODIES
|
|
MX349901B
(es)
|
2011-01-13 |
2017-08-18 |
Regeneron Pharma |
Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos.
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
KR101397088B1
(ko)
|
2011-06-10 |
2014-05-19 |
강원대학교산학협력단 |
암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
|
|
JO3370B1
(ar)
*
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
|
CN110078831A
(zh)
*
|
2011-12-01 |
2019-08-02 |
圆祥生命科技股份有限公司 |
补体和vegf途径的蛋白质抑制剂及其使用方法
|
|
CN103304668B
(zh)
*
|
2012-03-12 |
2015-10-28 |
江苏健德生物药业有限公司 |
Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
|
|
DK2846836T3
(da)
|
2012-05-07 |
2019-11-11 |
Allergan Inc |
Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi
|
|
WO2014006113A1
(en)
|
2012-07-03 |
2014-01-09 |
Sanofi |
Method of treating cancer by effective amounts of aflibercept
|
|
TW201438736A
(zh)
|
2012-11-14 |
2014-10-16 |
Regeneron Pharma |
以ｄｌｌ４拮抗劑治療卵巢癌之方法
|
|
WO2014124487A1
(en)
|
2013-02-18 |
2014-08-21 |
Vegenics Pty Limited |
Ligand binding molecules and uses thereof
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
CN104193828B
(zh)
*
|
2013-09-12 |
2017-04-05 |
北京韩美药品有限公司 |
同时阻断her2和vegfr信号通路的重组融合蛋白
|
|
DK3065761T3
(da)
|
2013-11-05 |
2020-02-17 |
Allergan Inc |
Fremgangsmåde til behandling af tilstande af øjet med en anti-vegf darpin
|
|
US20170232199A1
(en)
|
2014-05-12 |
2017-08-17 |
Formycon Ag |
Pre-Filled Plastic Syringe Containing a VEGF Antagonist
|
|
MX375557B
(es)
|
2014-07-18 |
2025-03-06 |
Sanofi Sa |
Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer.
|
|
JP2016036322A
(ja)
*
|
2014-08-11 |
2016-03-22 |
日本化薬株式会社 |
血管新生因子と結合するキメラタンパク質
|
|
SI3230316T1
(sl)
|
2014-12-11 |
2022-05-31 |
Bayer Healthcare Llc |
Zdravljenje starostne degeneracije makule z majhno aktivno horoidalno neovaskularizacijsko lezijo
|
|
GB201503453D0
(en)
|
2015-03-01 |
2015-04-15 |
Jain Arjun |
Endothelin-1"sponge"
|
|
TW202440903A
(zh)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（一）
|
|
WO2017046140A1
(en)
|
2015-09-18 |
2017-03-23 |
Bayer Pharma Aktiengesellschaft |
Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
|
|
WO2017065559A1
(ko)
|
2015-10-15 |
2017-04-20 |
(주)알테오젠 |
Igg fc 도메인을 가지는 융합 단백질의 생산방법
|
|
KR101936049B1
(ko)
*
|
2015-10-15 |
2019-01-08 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 생산방법
|
|
CA3005117C
(en)
|
2015-11-18 |
2023-01-24 |
Formycon Ag |
Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
|
|
KR20180083377A
(ko)
|
2015-11-18 |
2018-07-20 |
포르미콘 아게 |
Vegf 안타고니스트를 함유하는 사전충전형 플라스틱 주사기
|
|
CA3005132A1
(en)
|
2015-11-18 |
2017-05-26 |
Sio2 Medical Products, Inc. |
Coated syringe for ophthalmic formulations containing a vegf antagonist
|
|
CN108697792A
(zh)
*
|
2015-11-19 |
2018-10-23 |
珠海泰瑞尚生物医药科技有限公司 |
用于结合vegf的方法和组合物
|
|
MX2018006740A
(es)
|
2015-12-03 |
2018-08-01 |
Regeneron Pharma |
Metodos para asociar variantes geneticas con un resultado clinico en pacientes que sufren de degeneracion relacionada con la edad tratados con anti-factor de crecimiento endotelial vascular (vegf).
|
|
AU2017213103B2
(en)
|
2016-01-26 |
2022-08-11 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
|
US20190300607A1
(en)
|
2016-10-12 |
2019-10-03 |
Daiichi Sankyo Company, Limited |
Composition containing anti-robo4 antibody and other agents
|
|
CN116327963A
(zh)
|
2016-11-21 |
2023-06-27 |
济世-伊沃泰克生物制品有限公司 |
一种眼科制剂及其用途
|
|
EP3630062A2
(en)
|
2017-05-24 |
2020-04-08 |
SiO2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
WO2018217995A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
EP3668985B1
(en)
|
2017-08-17 |
2021-06-16 |
Just-Evotec Biologics, Inc. |
Method of purifying glycosylated protein from host cell galectins and other contaminants
|
|
MY202872A
(en)
|
2017-11-20 |
2024-05-28 |
Just Evotec Biologics Inc |
Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
|
|
CA3083472A1
(en)
*
|
2017-11-27 |
2019-05-31 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
|
MX2020005166A
(es)
|
2017-11-30 |
2020-09-03 |
Regeneron Pharma |
Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos.
|
|
EA039731B1
(ru)
*
|
2017-12-13 |
2022-03-04 |
Ридженерон Фармасьютикалз, Инк. |
Устройства и системы для управления опорой слоя сорбента хроматографической колонки и связанные с ними способы
|
|
IL310376B1
(en)
|
2018-01-26 |
2025-10-01 |
Univ California |
Methods and compositions for treating angiogenic disorders using anti-VEGF factors
|
|
CN112203679A
(zh)
|
2018-03-02 |
2021-01-08 |
科达制药股份有限公司 |
Il-6抗体及其融合构建体和缀合物
|
|
TW202016125A
(zh)
*
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
AU2019265005B2
(en)
|
2018-05-10 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
High concentration VEGF receptor fusion protein containing formulations
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
CN111378044B
(zh)
|
2018-12-28 |
2022-07-15 |
长春金赛药业有限责任公司 |
抗体融合蛋白、制备方法及其应用
|
|
US20220204920A1
(en)
|
2019-05-16 |
2022-06-30 |
Formycon Ag |
Method for reducing methionine oxidation in recombinant proteins
|
|
CA3150481A1
(en)
|
2019-09-03 |
2021-03-11 |
Amgen Inc. |
Injection device for drug delivery and packaging for the injection device
|
|
MX2022002980A
(es)
|
2019-09-16 |
2022-04-06 |
Amgen Inc |
Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
|
|
US11912784B2
(en)
|
2019-10-10 |
2024-02-27 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
CA3168512A1
(en)
|
2019-11-25 |
2021-06-03 |
Napoleone Ferrara |
Long-acting vegf inhibitors for intraocular neovascularization
|
|
IL293286A
(en)
|
2019-12-06 |
2022-07-01 |
Regeneron Pharma |
vegf mini-traps and methods of using them
|
|
EP4524236A3
(en)
|
2019-12-06 |
2025-07-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-vegf protein compositions and methods for producing the same
|
|
AU2021226754A1
(en)
|
2020-02-24 |
2022-07-07 |
Amgen Inc. |
Containers and systems for use during external sterilization of drug delivery devices
|
|
AU2021268026A1
(en)
|
2020-05-08 |
2023-01-19 |
Regeneron Pharmaceuticals, Inc. |
VEGF traps and mini-traps and methods for treating ocular disorders and cancer
|
|
BR112023022439A2
(pt)
|
2021-04-26 |
2023-12-26 |
Celanese Eva Performance Polymers Llc |
Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
|
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
|
US20250002557A1
(en)
|
2021-11-24 |
2025-01-02 |
Suzhou Light Ferry Biomed. Co., Ltd |
Multi-specific ligand-binding molecules and applications thereof
|
|
EP4549455A1
(en)
*
|
2022-08-02 |
2025-05-07 |
Panolos Bioscience, Inc. |
Modified fusion protein and use thereof
|
|
JP2025529465A
(ja)
|
2022-09-16 |
2025-09-04 |
チールー ファーマシューティカル カンパニー、リミテッド |
安定な高濃度自己緩衝医薬組成物
|
|
WO2025033876A1
(ko)
*
|
2023-08-04 |
2025-02-13 |
주식회사 파노로스바이오사이언스 |
변형된 융합 단백질과 scFv의 결합체 및 이의 용도
|
|
WO2025213011A1
(en)
|
2024-04-05 |
2025-10-09 |
Amgen Inc. |
Method of assessing stopper movement in a drug delivery device
|